GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensorion SA (XPAR:ALSEN) » Definitions » Total Receivables

Sensorion (XPAR:ALSEN) Total Receivables : €0.38 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sensorion Total Receivables?

Sensorion's Total Receivables for the quarter that ended in Dec. 2024 was €0.38 Mil.


Sensorion Total Receivables Historical Data

The historical data trend for Sensorion's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensorion Total Receivables Chart

Sensorion Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.47 0.22 0.21 0.38

Sensorion Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.50 0.21 0.57 0.38

Sensorion Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Sensorion Total Receivables Related Terms

Thank you for viewing the detailed overview of Sensorion's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensorion Business Description

Traded in Other Exchanges
Address
375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.

Sensorion Headlines

No Headlines